menu ☰
menu ˟

Luminate meets primary endpoint in phase 2b trial for DME

09 Aug 2017
Allegro Ophthalmics’ phase n2b stage 2 DEL MAR study of Luminate for diabetic macular edema has met its primary endpoint, according to a company press release.The double-masked, placebo-controlled, randomized, multicenter clinical trial had five ar...

Click here to view the full article which appeared in Opthalmology

IPH Logo